Ingunn R. Hullstein

Ingunn R. Hullstein

Auto-generated profile, based on publicly available information

Ingunn R. Hullstein

Norwegian Doping Control Laboratory, Department of Pharmacology, Oslo University Hospital , Oslo

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2023 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
PDF file
RARang Abdullah
Rang Abdullah
ABAstrid Bjørnebekk
Astrid Bjørnebekk
LHLisa E Hauger
Lisa E Hauger
IHIngunn R Hullstein
Ingunn R Hullstein
TEThor Edvardsen
Thor Edvardsen
VAVibeke Marie Almaas
Vibeke Marie Almaas
Aims: This study aims to explore the cardiovascular effects of long-term anabolic–androgenic steroid (AAS) use in both current and former weightlifting AAS users and estimate the occurrence of severe reduced myocardial function and the impact of duration and amount of AAS. Methods and results: In this cross-sectional study, 101 weightlifting AAS users with at least 1 year cumulative AAS use (mean 11 ± 7 accumulated years of AAS use) were compared with 71 non-using weightlifting controls (WLC) using clinical data and echocardiography. Sixty-nine were current, 30 former (>1 year since quitted), and 2 AAS users were not available for this classification. Anabolic–androgenic users had higher left ventricular mass index (LVMI) (106 ± 26 vs. 80 ± 15 g/m2, P < 0.001), worse left ventricular ejection fraction (LVEF) (49 ±7 vs. 59 ± 5%, P < 0.001) and right ventricular global longitudinal strain (−17.3 ± 3.5 vs. −22.8 ± 2.0%, P < 0.001), and higher systolic blood pressure (141 ± 17 vs. 133 ± 11 mmHg, P < 0.001) compared with WLC. In current users, accumulated duration of AAS use was 12 ± 7 years and in former 9 ± 6 years (quitted 6 ± 6 years earlier). Compared with WLC, LVMI and LVEF were pathological in current and former users (P < 0.05) with equal distribution of severely reduced myocardial function (LVEF ≤40%) (11 vs. 10%, not significant (NS)). In current users, estimated lifetime AAS dose correlated with reduced LVEF and LVGLS, P < 0.05, but not with LVMI, P = 0.12. Regression analyses of the total population showed that the strongest determinant of reduced LVEF was not coexisting strength training or hypertension but history of AAS use (β −0.53, P < 0.001). Conclusion: Long-term AAS users showed severely biventricular cardiomyopathy. The reduced systolic function was also found upon discontinued use.

6 September 2023 in medRxiv
Verified
Preprint
Open access
PDF file
RARang Abdullah
Rang Abdullah
ABAstrid Bjørnebekk
Astrid Bjørnebekk
LHLisa E. Hauger
Lisa E. Hauger
IHIngunn R. Hullstein
Ingunn R. Hullstein
TEThor Edvardsen
Thor Edvardsen
VAVibeke Marie Almaas
Vibeke Marie Almaas
Aims: Explore the cardiovascular effects of long-term anabolic-androgenic steroid (AAS)-use in both current and former weightlifting AAS-users, and estimate the occurrence of severe reduced myocardial function and the impact of duration and amount of AAS. Methods: In this cross-sectional study 101 weightlifting AAS-users with at least one year cumulative AAS-use (mean 11±7 accumulated years of AAS-use) were compared to 71 non-using weightlifting controls (WLC) using clinical data and echocardiography. Results: Sixty-nine were current, 30 former (> 1 year since quitted), and 2 AAS-users were not available for this classification. AAS-users had higher left ventricular mass index (LVMI) (106±26 versus 80±15 g/m 2 , P<0.001), worse LV ejection fraction (LVEF) (49±7 versus 59±5%, P<0.001) and right ventricular global longitudinal strain (RVGLS) (−17.3±3.5 versus −22.8±2.0%, P<0.001), and higher systolic blood pressure (SBP) (141±17 vs. 133±11 mmHg, p<0.001) compared with WLC. In current users accumulated duration of AAS-use was 12±7 years, and in former 9±6 years (quitted 6±6 years earlier). Compared to WLC, LVMI and LVEF were pathological in current and former users (p<0.05) with equal distribution of severely reduced myocardial function (LVEF ≤40%) (11% vs. 10%, NS). In current users estimated life time AAS-dose correlated with reduced LVEF and LVGLS, p<0.05, but not with LVMI, p=0.12. Regression analyses of the total population showed that the strongest determinant of reduced LVEF were not coexisting strength training or hypertension, but history of AAS-use (β −0.53, P<0.001). Conclusions: Long-term AAS-users showed severely biventricular cardiomyopathy. The reduced systolic function was also found upon discountied use.

12 October 2026 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
RARang Abdullah
Rang Abdullah
ABAstrid Bjørnebekk
Astrid Bjørnebekk
IHIngunn R Hullstein
Ingunn R Hullstein
PTPer Medbøe Thorsby
Per Medbøe Thorsby
THThomas Helle-Valle
Thomas Helle-Valle
VAVibeke Marie Almaas
Vibeke Marie Almaas
Aims: Anabolic–androgenic steroid (AAS) use is prevalent among men engaged in strength training and is associated with adverse structural and functional cardiac changes, but longitudinal data are lacking. This follow-up study examined myocardial effects of AAS with continued use and reversibility following discontinuation. Methods and results: Participants of a previously published cohort (2017–19) of 101 AAS users and 71 non-using weightlifting controls (WLCs) were invited for a follow-up study and underwent interviews, hormonal profiling, and transthoracic echocardiography. Current AAS users at baseline were continued or discontinued users at follow-up, while former users at baseline were those with continued abstinence and those who relapsed. Among those re-enrolled, 70 were AAS users, of whom 35 continued, 15 discontinued, 14 maintained abstinence, and 6 relapsed, and 35 were WLCs. Continued AAS users had persistent indexed left ventricular mass (LVMI 119 ± 30 g/m2), reduced LV ejection fraction (LVEF 48 ± 10%), and worsened diastolic function. Continued AAS users receiving antihypertensive therapy showed improved LVEF compared with untreated users (Δ = 5 ± 8 vs. −4 ± 8%, P = 0.005). Discontinued AAS users showed reduction in LVMI (Δ = −21 g/m2, P = 0.01) and improved LVEF (Δ = 6%, P < 0.001). At follow-up, these changes were comparable with WLCs, which showed statistically but clinically insignificant differences. Conclusion: Continued AAS use was associated with sustained LV hypertrophy, LV systolic dysfunction, and worsening diastolic function. Antihypertensive therapy among ongoing AAS users was associated with improved LV systolic function. Discontinuation of AAS use was associated with improvement in cardiac structure and function towards values observed in WLCs.